Clinical Trial

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060304 in Healthy and Elevated LDL-C Subjects.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-06-26; most recent amendment 2026-03-12.
Status change: Recruiting → Active, Not Recruiting 2026-03-12
Status change: Not Yet Recruiting → Recruiting 2025-08-12
Trial Details
NCT Number NCT06485245
Lead Sponsor Cascade Pharmaceuticals, Inc
Conditions MASH
Enrollment 80 participants
Start Date 2025-04-22
Primary Completion 2025-11-20 (estimated)
Study Completion 2026-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-13